Autopsy report · NCT05171166

Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.

“Difficult to enroll participants”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 3 years 10 months before it stopped.
• 18 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

Peking University

Sponsor type

University, hospital or other

Conditions

Hepatocellular Carcinoma

Interventions

HAIC; TACE; FOLFOX; cTACE or DEB-TACE; Donafenib

Participants

18

Sites

1

Countries

China

Trials that died the same way

• Efficacy and Safety of Empagliflozin in NODAT
  “Difficult in enrolling suitable participants” (94% match in meaning)
• Effect of Darbepoetin in Contrast-induced Nephropathy
  “difficult to enroll targeted participants” (92% match in meaning)
• Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
  “because of difficulties of enrolling appropriate participants” (84% match in meaning)
• PREGBRAIN - Magnetic Stimulation of the Brain in Depressed Pregnant Women
  “Difficult to recruit participants” (83% match in meaning)
• Effect of Luteal Progesterone Support on Pregnancy Rates With Combined Clomid/ Gonadotropin & IUI
  “unable to enroll participants who meet the criteria” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.